Abstract:Mitochondria are an essential intracellular organelle for medication targeting and delivery since they seem to create energy and conduct many other cellular tasks, and mitochondrial dysfunctions and malfunctions lead to many illnesses. Many initiatives have been taken to detect, diagnose, and image mitochondrial abnormalities, and to transport and accumulate medicines precisely to mitochondria, all because of special mitochondrial aspects of the pathophysiology of cancer. In addition to the negative membrane potential and paradoxical mitochondrial dynamics, they include high temperatures, high levels of reactive oxygen species, high levels of glutathione, and high temperatures. Neurodegenerative diseases represent a broad spectrum of debilitating illnesses. They are linked to the loss of certain groups of neurons based on an individual's physiology or anatomy. The mitochondria in a cell are generally accepted as the authority with respect to ATP production. Disruption of this system is linked to several cellular physiological issues. The development of neurodegenerative disorders has been linked to mitochondrial malfunction, according to pathophysiological studies. There seems to be substantial evidence connecting mitochondrial dysfunction and oxidative stress to the development of neurodegenerative disorders. It has been extensively observed that mitochondrial malfunction triggers autophagy, which plays a role in neurodegenerative disorders. In addition, excitotoxicity and mitochondrial dysfunction have been linked to the development of neurodegenerative disorders. The pathophysiology of neurodegenerative illnesses has been linked to increased apoptosis and necrosis, as well as mitochondrial malfunction. A variety of synthetic and natural treatments have shown efficacy in treating neurodegenerative illnesses caused by mitochondrial failure. Neurodegenerative illnesses can be effectively treated with existing drugs that target mitochondria, although their precise formulations are poorly understood. Therefore, there is an immediate need to focus on creating drug delivery methods specifically targeted at mitochondria in the treatment and diagnosis of neurodegenerative disorders.

Mitochondrial Targets for Pharmacological Intervention in Human Disease

Cell Models and Drug Discovery for Mitochondrial Diseases

Mitochondrial-Targeted Drug and DNA Delivery

Mitochondria-Targeted Drugs

Targeting Mitochondrial Impairment in Parkinson's Disease: Challenges and Opportunities

Unlocking mitochondrial drug targets: The importance of mitochondrial transport proteins

An Insight into the Approach Taken to Appurtenances Disorders Linked to Mitochondria

Mitochondrial Targeting of Probes and Therapeutics to the Powerhouse of the Cell

Mitochondria as a therapeutic target for common pathologies

Mitochondrial Unfolded Protein Response and Integrated Stress Response as Promising Therapeutic Targets for Mitochondrial Diseases

Mitochondrial dysfunction: mechanisms and advances in therapy

Pharmacological Progress of Mitophagy Regulation

Mitochondrial-targeted liposome-based drug delivery – therapeutic potential and challenges

Potential indicators of mitochondrial structure and function.

Targeted Treatment Strategies for Mitochondria Dysfunction: Correlation with Neurological Disorders

Targeting the mitochondrial permeability transition pore for drug discovery: Challenges and opportunities

Investigating Therapies Targeting Druggable Targets of Mitochondria: Exploring the Efficacy for the Treatment of Cancer

Targeting mitochondrial quality control: new therapeutic strategies for major diseases

Targeted Mitochondrial Nanomaterials in Biomedicine: Advances in Therapeutic Strategies and Imaging Modalities

Recent Advances in Chemical Biology of Mitochondria Targeting